Zhiyao He

Dr. Zhiyao He

West China Hospital of Sichuan University, Chengdu, Sichuan, China
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 June 2021 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
LCLi Chen
Li Chen
WHWeiqi Hong
Weiqi Hong
WRWenyan Ren
Wenyan Ren
TXTing Xu
Ting Xu
ZQZhiyong Qian
Zhiyong Qian
Zhiyao HeZhiyao He
Zhiyao He
Over the past decades, great interest has been given to biomimetic nanoparticles (BNPs) since the rise of targeted drug delivery systems and biomimetic nanotechnology. Biological vectors including cell membranes, extracellular vesicles (EVs), and viruses are considered promising candidates for targeted delivery owing to their biocompatibility and biodegradability. BNPs, the integration of biological vectors and functional agents, are anticipated to load cargos or camouflage synthetic nanoparticles to achieve targeted delivery. Despite their excellent intrinsic properties, natural vectors are deliberately modified to endow multiple functions such as good permeability, improved loading capability, and high specificity. Through structural modification and transformation of the vectors, they are pervasively utilized as more effective vehicles that can deliver contrast agents, chemotherapy drugs, nucleic acids, and genes to target sites for refractory disease therapy. This review summarizes recent advances in targeted delivery vectors based on cell membranes, EVs, and viruses, highlighting the potential applications of BNPs in the fields of biomedical imaging and therapy industry, as well as discussing the possibility of clinical translation and exploitation trend of these BNPs.

1 May 2020 in Biotechnology Advances
Verified
Journal Article
Closed access
CMCui-Cui Ma
Cui-Cui Ma
ZWZhen-Ling Wang
Zhen-Ling Wang
TXTing Xu
Ting Xu
Zhiyao HeZhiyao He
Zhiyao He
YWYu-Quan Wei
Yu-Quan Wei

23 January 2015 in Cell Research
Verified
Journal Article
Open access
PDF file
XWXiawei Wei
Xiawei Wei
BSBin Shao
Bin Shao
Zhiyao HeZhiyao He
Zhiyao He
TYTinghong Ye
Tinghong Ye
MLMin Luo
Min Luo
ZZZhirong Zhang
Zhirong Zhang
Nanocarriers with positive surface charges are known for their toxicity which has limited their clinical applications. The mechanism underlying their toxicity, such as the induction of inflammatory response, remains largely unknown. In the present study we found that injection of cationic nanocarriers, including cationic liposomes, PEI, and chitosan, led to the rapid appearance of necrotic cells. Cell necrosis induced by cationic nanocarriers is dependent on their positive surface charges, but does not require RIP1 and Mlkl. Instead, intracellular Na+ overload was found to accompany the cell death. Depletion of Na+ in culture medium or pretreatment of cells with the Na+/K+-ATPase cation-binding site inhibitor ouabain, protected cells from cell necrosis. Moreover, treatment with cationic nanocarriers inhibited Na+/K+-ATPase activity both in vitro and in vivo. The computational simulation showed that cationic carriers could interact with cation-binding site of Na+/K+-ATPase. Mice pretreated with a small dose of ouabain showed improved survival after injection of a lethal dose of cationic nanocarriers. Further analyses suggest that cell necrosis induced by cationic nanocarriers and the resulting leakage of mitochondrial DNA could trigger severe inflammation in vivo, which is mediated by a pathway involving TLR9 and MyD88 signaling. Taken together, our results reveal a novel mechanism whereby cationic nanocarriers induce acute cell necrosis through the interaction with Na+/K+-ATPase, with the subsequent exposure of mitochondrial damage-associated molecular patterns as a key event that mediates the inflammatory responses. Our study has important implications for evaluating the biocompatibility of nanocarriers and designing better and safer ones for drug delivery.

17 November 2016 in ACS Nano
Verified
Journal Article
Closed access
LLLing Li
Ling Li
LSLinjiang Song
Linjiang Song
XLXiaowei Liu
Xiaowei Liu
XYXi Yang
Xi Yang
XLXia Li
Xia Li
YWYuquan Wei
Yuquan Wei

1 July 2015 in Human Gene Therapy
Verified
Journal Article
Closed access
LLLing Li
Ling Li
Zhiyao HeZhiyao He
Zhiyao He
XWXia-Wei Wei
Xia-Wei Wei
GGGuang-Ping Gao
Guang-Ping Gao
YWYu-Quan Wei
Yu-Quan Wei
CRISPR/Cas9 genome editing platforms are widely applied as powerful tools in basic research and potential therapeutics for genome regulation. The appropriate alternative of delivery system is critical if genome editing systems are to be effectively performed in the targeted cells or organisms. To date, the in vivo delivery of the Cas9 system remains challenging. Both physical methods and viral vectors are adopted in the delivery of the Cas9-based gene editing platform. However, physical methods are more applicable for in vitro delivery, while viral vectors are generally concerned with safety issues, limited packing capacities, and so on. With the robust development of nonviral drug delivery systems, lipid- or polymer-based nanocarriers might be potent vectors for the delivery of CRISPR/Cas9 systems. In this review, we look back at the delivery approaches that have been used for the delivery of the Cas9 system and outline the recent development of nonviral vectors that might be potential carriers for the genome editing platform in the future. The efforts in optimizing cationic nanocarriers with structural modification are described and promising nonviral vectors under clinical investigations are highlighted.

22 January 2020 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
YTYan Tie
Yan Tie
HZHeng Zheng
Heng Zheng
Zhiyao HeZhiyao He
Zhiyao He
JYJingyun Yang
Jingyun Yang
BSBin Shao
Bin Shao
XWXiawei Wei
Xiawei Wei
Tumor-associated macrophages (TAMs) facilitate cancer progression by promoting tumor invasion, angiogenesis, metastasis, inflammatory responses, and immunosuppression. Folate receptor β (FRβ) is overexpressed in TAMs. However, the clinical significance of FRβ-positive macrophages in lung cancer remains poorly understood. In this study, we verified that FRβ overexpression in lung cancer TAMs was associated with poor prognosis. We utilized a folate-modified lipoplex comprising a folate-modified liposome (F-PLP) delivering a BIM-S plasmid to target both lung cancer cells and FRβ-positive macrophages in the tumor microenvironment. Transfection of LL/2 cells and MH-S cells with F-PLP/pBIM induced cell apoptosis. Injection of F-PLP/pBIM into LL/2 and A549 lung cancer models significantly depleted FRβ-positive macrophages and reduced tumor growth. Treatment of tumor-bearing mice with F-PLP/pBIM significantly inhibited tumor growth in vivo by inducing tumor cell and macrophage apoptosis, reducing tumor proliferation, and inhibiting tumor angiogenesis. In addition, a preliminary safety evaluation demonstrated a good safety profile of F-PLP/pBIM as a gene therapy administered intravenously. This work describes a novel application of lipoplexes in lung cancer targeted therapy that influences the tumor microenvironment by targeting TAMs.